CatSci partners with three leading UK organisations to offer expert support across the pharmaceutical supply chain

Cardiff, UK – CatSci Ltd, a scientifically led, commercially minded and award-winning innovation partner, today announced partnerships with three UK companies across the pharmaceutical supply chain – M2M Pharmaceuticals (M2M Pharma), New Path Molecular (NPM) and Upperton Pharma Solutions (Upperton). This will provide CatSci’s customers with access to specialised capabilities and expertise, ensuring they can develop affordable, best-in-class small molecule therapeutics that meet their evolving healthcare needs.

CatSci provides tailored process research and development services for its customers, but this is not the only step in the drug development supply chain. By partnering with these three leading companies with extensive expertise in their respective fields, CatSci can offer enhanced strategic value to its customers throughout the journey from molecule to medicine.

M2M Pharma, based in Reading, provides material characterisation for pharmaceuticals, offering customers the next step in their medicines manufacturing process following CatSci’s rigorous drug substance development.

Upperton, located in Nottingham, supports the next step in the supply chain through pre-formulation, formulation and drug product services. This includes GMP spray drying, as well as formulation for inhalation products and solid oral dose products.

CatSci has also partnered with New Path Molecular, based in Cambridge, who are industry leaders in flow chemistry and other machine-assisted technologies. CatSci predominately specialises in batch chemistry, so NPM can provide continuous processing services to customers who may benefit from access to this technology.

Collaborating with these partners ensures that CatSci’s customers have access to curated support across the supply chain. Seamless technological transfer will be enabled through strong communication and the close, 100-mile, geographic radius that all four companies operate within. These partnerships will help CatSci maintain its expert services in-house while simultaneously aiding customers throughout their drug development and manufacturing journey.

Dr Ross Burn, CEO at CatSci, said: “We have found a way to immediately add value and specialised expertise to our customers’ projects without diluting CatSci’s capabilities and experience. By creating this network of trusted partners, CatSci is ensuring that our customers’ needs are met end-to-end, no matter the project demands.”

Dr Richard Johnson, CEO at Upperton, said: “Upperton sees great value in collaborating with other like-minded companies that can add value to our business and enhance the speed at which our customer’s products progress to market. We see great value in this exciting new partnership with CatSci. The combined expertise that this new consortium brings will certainly enhance the services that we can provide for our customers.”

 

Dr Mridul Majumder, Founder & Director at M2M Pharma, said: “Pharmaceutical product development is a long-haul journey that requires money, expertise, facilities and time. However, the most important aspect is collaboration, without which success is limited. Therefore, when Ross visited us in August 2020 and proposed this partnership with CatSci and other companies, it was an easy yes from our side to participate in this journey. We look forward to working with this partnership and I am convinced that together we will achieve more.”

 

Dr Elizabeth Farrant, CEO at New Path Molecular, said: “We are delighted to be partnering with CatSci, with their proven expertise in batch process research and development. We are looking forward to providing our know-how in flow chemistry and continuous processing to customers who will benefit from this cutting-edge technology.”